Search results for "Oncogene"

showing 10 items of 1005 documents

Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation.

2002

Platelet concentrates (PC) are increasingly used to increase bone regeneration in pre-prosthetic surgery. Although it is generally appreciated that certain growth factors (PDGF, TGF, EGF, and ECGF) are present in thrombocyte preparations, relatively little is known about these components in quantitative terms. The study reported here analysed the amounts of growth factors in PC produced under standard conditions from healthy volunteers. All the blood samples (237 in total) were analysed using Quantikine ELISA kits (R and D). The mean +/- SD platelet count in whole blood from these donors was 262,000+/-58,000/microl, while in PC produced by discontinuous cell separation it was 1.419,000+/-33…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorTime Factorsmedicine.medical_treatmentClinical BiochemistryBecaplerminEnzyme-Linked Immunosorbent AssayCell SeparationTransforming Growth Factor beta1chemistry.chemical_compoundInsulin-like growth factorTransforming Growth Factor beta2EndocrinologySex FactorsTransforming Growth Factor betaInternal medicinemedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesWhole bloodAgedPlatelet-Derived Growth FactorChromatographybiologyChemistryGrowth factorCell BiologyProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyPlatelet-rich plasmabiology.proteinFemalePlatelet-derived growth factor receptorGrowth factors (Chur, Switzerland)
researchProduct

Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

2017

Summary T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the pathogenesis of several autoimmune diseases. The exact role of IL-9 and Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β expression were assessed in skin and kidney biopsies of SSc patients and healthy controls (HC) by immunohistochemistry (IHC). The cellular source of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-producing cells were also studied by flow cytometry. The functional relevance of IL-9 increased expression in SSc …

AdultCD4-Positive T-LymphocytesMale0301 basic medicineIL-9 ILC2 systemic sclerosis Th9Thymic stromal lymphopoietinNeutrophilsImmunologyExtracellular TrapsPeripheral blood mononuclear cellFlow cytometryILC2Pathogenesis03 medical and health sciencesThymic Stromal LymphopoietinTransforming Growth Factor betaProto-Oncogene ProteinsmedicineHumansImmunology and AllergyTh9Interleukin 9Mast CellsAutoantibodiesSkinReceptors Interleukin-9B-LymphocytesScleroderma Systemicmedicine.diagnostic_testintegumentary systembusiness.industryInterleukin-9InterleukinCell DifferentiationOriginal ArticlesNeutrophil extracellular trapsMiddle AgedIL-9Settore MED/16 - Reumatologia030104 developmental biologyImmunologyTrans-ActivatorsCytokinesImmunohistochemistryFemaleInterleukin-4businesssystemic sclerosi
researchProduct

Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on rac proteins

2006

Abstract We have shown recently that the azathioprine metabolite 6-Thio-GTP causes immunosuppression by blockade of GTPase activation in T lymphocytes. In the present study, we describe a new molecular mechanism by which 6-Thio-GTP blocks GTPase activation. Although 6-Thio-GTP could bind to various small GTPases, it specifically blocked activation of Rac1 and Rac2 but not of closely related Rho family members such as Cdc42 and RhoA in primary T cells upon stimulation with αCD28 or fibronectin. Binding of 6-Thio-GTP to Rac1 did not suppress Rac effector coupling directly but blocked Vav1 exchange activity upon 6-Thio-GTP hydrolysis, suggesting that 6-Thio-GTP loading leads to accumulation of…

AdultCD4-Positive T-LymphocytesVAV1RHOAT cellImmunologyBlotting WesternAntigen-Presenting CellsFluorescent Antibody TechniqueRAC1ApoptosisEnzyme-Linked Immunosorbent AssayGTPaseCell CommunicationBiologyArticleAzathioprinemedicineImmunology and AllergyHumansAntigen-presenting cellProto-Oncogene Proteins c-vavNeurofibromin 2Flow CytometryMolecular biologyCell biologyrac GTP-Binding ProteinsRac GTP-Binding ProteinsEnzyme Activationmedicine.anatomical_structurebiology.proteinSignal transductionImmunosuppressive Agents
researchProduct

Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance.

2000

The metabolic microenvironment of a tumor is predominantly determined by the efficacy of blood flow, flux parameters (such as diffusion and convective currents in the interstitial space) and metabolic rates. The most important factors in this context include oxygen and nutrient supply, tissue pH and the bioenergetic status. It is now widely accepted that the metabolic microenvironment of a tumor can dramatically influence a range of factors such as proliferation rate, cell cycle position, growth rate and the development of apoptosis and necrosis. At the same time, these parameters can have an impact on tumor detection, therapeutic response to conventional irradiation, some chemotherapy agen…

AdultCancer ResearchMammary glandAntineoplastic AgentsBreast NeoplasmsBiologyRadiation ToleranceMetastasisMicrocirculationOxygen ConsumptionInterstitial spacemedicinePressureHumansAgedOncogeneNeovascularization PathologicMicrocirculationCancerCell cycleHydrogen-Ion ConcentrationMiddle Agedmedicine.diseaseMolecular medicineCell HypoxiaBody FluidsOxygenmedicine.anatomical_structureOncologyImmunologyCancer researchFemaleMenopauseEnergy MetabolismBlood Flow VelocityCell DivisionInternational journal of oncology
researchProduct

bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus

1996

The bcl-2 proto-oncogene is a known inhibitor of apoptosis and may be an important regulator of tumor growth. In the present study, bcl-2-protein expression was investigated by immunohistochemistry and correlated with prognosis in a series of 150 potentially curatively resected squamous-cell carcinomas of the esophagus. For comparison, bcl-2-protein expression was analyzed in normal esophageal mucosa, severe squamous dysplasias and carcinomas in situ. bcl-2 immunoreactivity was found in 40 out of 150 invasive squamous-cell carcinomas; the remaining carcinomas were completely negative. bcl-2-protein expression was found more frequently among poorly differentiated than among well-differentiat…

AdultCancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsCellGene ExpressionBiologyInhibitor of apoptosisProto-Oncogene MasProto-Oncogene ProteinsGene expressionmedicineHumansEsophagusAgedAged 80 and overMucous MembraneEsophageal diseaseMiddle AgedEsophageal cancerPrognosismedicine.diseaseSurvival Ratemedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryCarcinoma in SituInternational Journal of Cancer
researchProduct

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

2007

Persistent infection with human papillomaviruses (HPV) is a prerequisite for the development of cervical cancer. Vaccination with virus-like particles (VLP) has demonstrated efficacy in prophylaxis but lacks therapeutic potential. HPV16 L1E7 chimeric virus-like particles (CVLP) consist of a carboxy-terminally truncated HPV16L1 protein fused to the amino-terminal part of the HPV16 E7 protein and self-assemble by recombinant expression of the fusion protein. The CVLP are able to induce L1- and E7-specific cytotoxic T lymphocytes. We have performed a first clinical trial to gain information about the safety and to generate preliminary data on the therapeutic potential of the CVLP in humans. A …

AdultCancer ResearchTime FactorsOncogene Proteins FusionvirusesUterine Cervical NeoplasmsCervical intraepithelial neoplasiaCancer VaccinesDrug Administration ScheduleDouble-Blind MethodMedicineHumansPapillomavirus VaccinesAdverse effectAgedCervical cancerHuman papillomavirus 16biologybusiness.industryPapillomavirus Infectionsvirus diseasesOncogene Proteins ViralMiddle Agedmedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsVaccinationClinical trialTumor Virus InfectionsTreatment OutcomeOncologyImmunizationHigh Grade Cervical Intraepithelial NeoplasiaImmunologyDNA Viralbiology.proteinFemaleAntibodybusinessInternational journal of cancer
researchProduct

Prospective study on cervical neoplasia IV. Presence of HPV antibodies.

1999

Sera collected in the course of a prospective study carried out in Prague in 1975–1983 were assayed for the presence of human papillomavirus (HPV) antibodies. Women with cervical neoplasia proven by biopsy at enrollment possessed antibodies to peptides derived from E2, E4 and E7 proteins of HPV16 and to virus-like particles (VLPs) of HPV16, -18 and -33 significantly more frequently than matched controls. Women without cervical neoplasia at enrollment who developed the disease in the course of the study differed from matched controls by a higher prevalence of antibodies against VLPs of HPV16 and -18 but not against early antigens of HPV16. In 19 of the latter subjects, paired serum specimens…

AdultCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsUterine Cervical NeoplasmsAntibodies ViralGastroenterologySerologyAntigenInternal medicineBiopsymedicineHumansProspective StudiesSeroconversionProspective cohort studyPapillomaviridaebiologymedicine.diagnostic_testbusiness.industryvirus diseasesCancerOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsDNA-Binding ProteinsOncologyImmunologybiology.proteinFemaleViral diseaseAntibodybusinessBiomarkersInternational journal of cancer
researchProduct

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

2010

A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene fo…

AdultCyclin-Dependent Kinase Inhibitor p21MaleGenotypeHealth Toxicology and MutagenesisClinical BiochemistryBlack PeopleBiologyPolymorphism Single NucleotideBiochemistryWhite PeopleYoung AdultGene FrequencyRisk FactorsGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleYoung adultSarcoma KaposiKaposi's sarcomaAllele frequencyAgedAged 80 and overProto-Oncogene Proteins c-mdm2Odds ratioMiddle Agedmedicine.diseaseConfidence intervalImmunologyCancer researchFemaleSarcomaTumor Suppressor Protein p53
researchProduct

Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors.

2001

The EWS-ETS rearrangements, and their respective fusion gene products, are specifically associated with histopathologically Ewing family tumors (EFT). These translocations are implicated in generating malignant transformation of EFT, but the presence of additional genetic alterations must be considered in the pathogenesis of such tumors. We analyzed 26 samples (biopsies and/or nude mice xenotransplants) collected from 19 patients with an EFT to determine whether molecular and cytogenetic alterations of the G(1)/S checkpoint genes are implicated in the pathogenesis of EFT. We found inactivating p53 mutations in three (16%) cases, which correlated with a loss of p21(WAF1/Cip1) expression and …

AdultCyclin-Dependent Kinase Inhibitor p21MaleMonosomyTumor suppressor geneAdolescentTransplantation HeterologousGene ExpressionChromosome 9Locus (genetics)Sarcoma EwingBiologymedicine.disease_causePathology and Forensic MedicineFusion geneMiceCyclinsProto-Oncogene ProteinsmedicineAnimalsHumansPoint MutationCyclin D1ChildMolecular BiologyGeneGene AmplificationChromosome MappingCyclin-Dependent Kinase 4Nuclear ProteinsProto-Oncogene Proteins c-mdm2Cell BiologyDNA Methylationmedicine.diseaseGenes p53Survival AnalysisCyclin-Dependent KinasesChromosome 17 (human)Child PreschoolCancer researchFemaleCarcinogenesisChromosomes Human Pair 9Gene DeletionNeoplasm TransplantationLaboratory investigation; a journal of technical methods and pathology
researchProduct

Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia.

2003

The Philadelphia (Ph) chromosome is found in more than 90% of chronic myelocytic leukemia (CML) patients. In most cases, it results from the reciprocal t(9;22)(q34;q11), with the ABL proto-oncogene from 9q34 fused to the breakpoint cluster region (BCR) locus on 22q11. In 5%-10% of patients with CML, the Ph chromosome originates from variant translocations, involving various breakpoints in addition to 9q34 and 22q11. In our investigation, three CML cases with complex Ph translocations have been analyzed by G-banding and fluorescence in situ hybridization (FISH). FISH with breakpoint-spanning probes for the BCR and ABL genes revealed information about the genesis of complex Ph translocations.…

AdultGenetic MarkersMaleCancer Researchmedicine.medical_specialtyChromosomes Human Pair 22Chromosomal translocationLocus (genetics)BiologyPhiladelphia chromosomeProto-Oncogene MasTranslocation Genetichemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositiveGeneticsmedicineHumansPhiladelphia ChromosomeMolecular BiologyIn Situ Hybridization FluorescenceGeneticsABLmedicine.diagnostic_testChromosomes Human Pair 11BreakpointCytogeneticsbreakpoint cluster regionGenetic VariationMiddle Agedmedicine.diseaseChromosome BandingKaryotypingFemaleChromosomes Human Pair 9Fluorescence in situ hybridizationCancer genetics and cytogenetics
researchProduct